Maxigen Biotech Inc.
TWSE:1783.TW
45.5 (TWD) • At close September 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 622.115 | 604.431 | 511.976 | 457.691 | 452.199 | 427.68 | 427.561 | 336.388 | 261.469 | 245.686 | 232.947 | 221.997 | 178.876 | 172.44 | 180.604 |
| Cost of Revenue
| 198.021 | 230.439 | 250.949 | 243.171 | 234.927 | 245.112 | 267.276 | 201.471 | 169.938 | 149.616 | 125.738 | 120.434 | 127.901 | 107.941 | 101.575 |
| Gross Profit
| 424.094 | 373.992 | 261.027 | 214.52 | 217.272 | 182.568 | 160.285 | 134.917 | 91.531 | 96.07 | 107.209 | 101.563 | 50.975 | 64.499 | 79.029 |
| Gross Profit Ratio
| 0.682 | 0.619 | 0.51 | 0.469 | 0.48 | 0.427 | 0.375 | 0.401 | 0.35 | 0.391 | 0.46 | 0.457 | 0.285 | 0.374 | 0.438 |
| Reseach & Development Expenses
| 68.595 | 99.632 | 75.681 | 69.15 | 66.862 | 50.672 | 43.31 | 36.259 | 48.744 | 32.799 | 32.415 | 34.407 | 26.328 | 25.104 | 21.33 |
| General & Administrative Expenses
| 72.568 | 63.013 | 52.842 | 50.182 | 44.622 | 44.859 | 46.878 | 60.435 | 51.928 | 42.704 | 39.581 | 35.108 | 32.045 | 32.401 | 22.924 |
| Selling & Marketing Expenses
| 132.882 | 78.015 | 39.533 | 34.18 | 40.298 | 40.908 | 49.049 | 49.535 | 51.383 | 49.17 | 38.772 | 42.721 | 34.239 | 37.928 | 27.465 |
| SG&A
| 205.45 | 141.028 | 92.375 | 84.362 | 84.92 | 85.767 | 95.927 | 109.97 | 103.311 | 91.874 | 78.353 | 77.829 | 66.284 | 70.329 | 50.389 |
| Other Expenses
| -274.244 | 34.051 | 7.234 | 15.106 | 10.605 | 15.136 | -0.236 | 4.167 | 0.724 | 11.342 | 8.657 | 10.213 | 5.036 | 15.298 | 5.152 |
| Operating Expenses
| 274.244 | 240.66 | 168.056 | 153.512 | 151.782 | 136.439 | 139.237 | 146.229 | 152.055 | 124.673 | 110.768 | 112.236 | 92.612 | 95.433 | 71.719 |
| Operating Income
| 149.85 | 170.564 | 100.686 | 76.889 | 76.095 | 46.129 | 21.048 | -11.312 | -60.524 | -28.603 | -3.559 | -10.673 | -41.637 | -30.934 | 7.31 |
| Operating Income Ratio
| 0.241 | 0.282 | 0.197 | 0.168 | 0.168 | 0.108 | 0.049 | -0.034 | -0.231 | -0.116 | -0.015 | -0.048 | -0.233 | -0.179 | 0.04 |
| Total Other Income Expenses Net
| 43.292 | -4.784 | -3.22 | -0.153 | -3.3 | 11.179 | -4.353 | -0.647 | -1.539 | 9.706 | 6.974 | 13.699 | 6.273 | 16.341 | 5.342 |
| Income Before Tax
| 193.142 | 165.78 | 97.466 | 76.736 | 72.795 | 57.308 | 16.695 | -11.959 | -62.063 | -18.897 | 3.415 | 3.026 | -35.364 | -14.593 | 12.652 |
| Income Before Tax Ratio
| 0.31 | 0.274 | 0.19 | 0.168 | 0.161 | 0.134 | 0.039 | -0.036 | -0.237 | -0.077 | 0.015 | 0.014 | -0.198 | -0.085 | 0.07 |
| Income Tax Expense
| 27.314 | 26.376 | 9.799 | 13.425 | 12.684 | 0.253 | 0.908 | 0.288 | 0.896 | 0.144 | 0.831 | 0.262 | 0.709 | 1.407 | 0.025 |
| Net Income
| 165.828 | 139.404 | 87.667 | 63.311 | 60.111 | 57.055 | 15.787 | -12.247 | -62.959 | -19.041 | 2.584 | 2.764 | -36.073 | -16 | 12.627 |
| Net Income Ratio
| 0.267 | 0.231 | 0.171 | 0.138 | 0.133 | 0.133 | 0.037 | -0.036 | -0.241 | -0.078 | 0.011 | 0.012 | -0.202 | -0.093 | 0.07 |
| EPS
| 1.86 | 1.57 | 1.05 | 0.79 | 0.75 | 0.67 | 0.21 | -0.16 | -0.81 | -0.25 | 0.036 | 0.046 | -0.65 | -0.29 | 0.28 |
| EPS Diluted
| 1.85 | 1.56 | 1.04 | 0.79 | 0.71 | 0.67 | 0.21 | -0.16 | -0.81 | -0.25 | 0.036 | 0.046 | -0.65 | -0.29 | 0.28 |
| EBITDA
| 220.957 | 200.146 | 133.587 | 110.081 | 108.586 | 87.511 | 46.58 | 10.971 | -47.577 | -10.512 | 11.749 | 8.082 | -19.635 | -19.623 | 18.241 |
| EBITDA Ratio
| 0.355 | 0.331 | 0.261 | 0.241 | 0.24 | 0.205 | 0.109 | 0.033 | -0.182 | -0.043 | 0.05 | 0.036 | -0.11 | -0.114 | 0.101 |